Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Journal for ImmunoTherapy of Cancer

Figure 1

From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Figure 1

The waterfall plot represents a number of target lesions for each patient using irRC simulating RECIST1.0 (dark gray bars) and irRC simulating RECIST1.1 (light gray bars). The number of target lesions by irRC simulating RECIST1.1 was significantly smaller than that by irRC simulating RECIST1.0 (P < 0.0001).

Back to article page